ABSTRACT
The authors of this chapter offer their experience in developing and administering advanced drug products in utero, including the rationale for prenatal somatic cell gene therapy, candidate diseases and preclinical studies, and prenatal testing. They then describe the limitations and risks of this innovative and impactful area of gene therapy research.
